SecBot SecBot

USTRx Act

S. 5265 Sen. Tim Sheehy (R-MT) In committee
Bill text PDF
  1. Introduced Aug 5
  2. Committee Aug 5
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Aug 5, 2026Next: Senate vote
84d ago Aug 5, 2026: Read twice and referred to the Committee on Finance.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Use Sovereignty To reduce Rx Act or the USTRx Act

Full summary3 paragraphs

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

Library of Congress summary, Aug 5, 2026

Summary versions
  • Introduced in SenateAug 5, 2026

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.